An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads-Reference-Cited by-同舟云学术

An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads

Published:2021-05 Issue:5 Volume:26 Page:1115-1125
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Chaudhry Charu^ORCID,Tebben Andrew,Tokarski John S.^ORCID,Borzilleri Robert,Pitts William J.,Lippy Jonathan,Zhang Litao

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference48 articles.

1. Kinase inhibitors: the road ahead;Ferguson;Nat. Rev. Drug Discov.,2018

2. Properties of FDA-approved small molecule protein kinase inhibitors;Roskoski;Pharmacol. Res.,2019

3. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571);Nagar;Cancer Res.,2002

4. Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine;Nakano;J. Antibiot.,2009

5. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity;Yun;Cancer Cell,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the roles of the Cdc2-like kinases in cancers;Bioorganic & Medicinal Chemistry;2022-09

2. Beyond Proteolysis-Targeting Chimeric Molecules: Designing Heterobifunctional Molecules Based on Functional Effectors;Journal of Medicinal Chemistry;2022-06-10

3. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling;Methods in Enzymology;2022

4. A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics;Drug Discovery Today;2021-12